



## Original Investigation

# FRAX-based assessment and intervention threshold curves for osteoporosis evaluation in Ecuador



Genesis Maldonado<sup>a,\*</sup>, María Intriago<sup>a</sup>, Roberto Guerrero<sup>a</sup>, Osvaldo Daniel Messina<sup>b</sup>, Carlos Ríos<sup>c</sup>

<sup>a</sup> Universidad Espíritu Santo, Guayaquil, Ecuador

<sup>b</sup> Hospital Cosme Argerich, Buenos Aires, Argentina

<sup>c</sup> Universidad Espíritu Santo, Guayaquil, Ecuador

### ARTICLE INFO

#### Article history:

Received 21 December 2019

Accepted 21 April 2020

Available online 25 July 2020

#### Keywords:

Assessment thresholds

FRAX

Intervention threshold

Ecuador

Osteoporosis

### ABSTRACT

**Introduction:** FRAX has been validated and adapted to different countries, covering almost 80% of the world's population, including Ecuador where it was adapted in 2009. The purpose of this study is to elaborate evaluation and intervention curves based on FRAX Ecuador.

**Methods:** Using the FRAX Ecuador model, we calculated the probability of a major osteoporotic fracture and a female hip fracture without any risk factor and without the inclusion of BMD. The probabilities were calculated in 5-year intervals from 40 to 90 years. The probabilities of major fractures and hip fractures were calculated in 3 different scenarios: 1. History of previous fracture without the inclusion of BMD, 2. T score -2.5 SD without other clinical risk factors, 3. T score -1.5 SD without other clinical risk factors.

**Results:** In women without risk factors, the probability of a major osteoporotic fracture increased with age from 0.4% at 40 years to 7.3% at 90 years. The probability of hip fracture increased with age from 0% at 40 years to 3.6% at 90 years. The probability of a major osteoporotic fracture increased in women with a T score of -2.5 SD from 0.9% at 40 years to 5.5% at 90 years; with a T-score of -1.5 SD, from 0.6% at 40 years to 3.9% at 90 years.

**Conclusion:** Data shows the importance of applying tools such as FRAX, specific for each country and also the creation of evaluation and intervention curves that allow discerning according to each patient the need for the use of resources such as DXA and specific treatments.

© 2020 Asociación Colombiana de Reumatología. Published by Elsevier España, S.L.U. All rights reserved.

\* Corresponding author.

E-mail address: [genesismaldonadovelez92@gmail.com](mailto:genesismaldonadovelez92@gmail.com) (G. Maldonado).

<https://doi.org/10.1016/j.rcreu.2020.04.004>

## Curvas de intervención y evaluación basadas en FRAX Ecuador

### RESUMEN

**Palabras clave:**

Curva de evaluación  
FRAX  
Curva de intervención  
Ecuador  
Osteoporosis

**Introducción:** La herramienta FRAX ha sido validada y adaptada a diferentes países, cubriendo a casi el 80% de la población mundial, incluido Ecuador, donde fue adaptada en 2009. El objetivo de este estudio fue elaborar curvas de evaluación e intervención basadas en FRAX Ecuador.

**Métodos:** Utilizando el modelo FRAX Ecuador, calculamos la probabilidad de fractura osteoporótica mayor y fractura de cadera femenina sin ningún factor de riesgo y sin la inclusión de DMO. Las probabilidades se calcularon en intervalos de 5 años de 40 a 90 años. Las probabilidades de fractura mayor y de cadera se calcularon en 3 escenarios diferentes: 1. Historia de fractura previa sin la inclusión de DMO, 2. T-Score de -2,5 SD sin otros factores de riesgo clínico, 3. T-Score -1,5 SD sin otros factores de riesgo clínico.

**Resultados:** En mujeres sin factores de riesgo, la probabilidad de fractura osteoporótica mayor aumentó con la edad del 0,4% a los 40 años al 7,3% a los 90 años. La probabilidad de fractura de cadera aumentó con la edad de 0% a los 40 años a 3,6% a los 90 años. La probabilidad de fractura osteoporótica mayor aumentó en mujeres con un puntaje T de -2,5 SD de 0,9% a los 40 años a 5,5% a los 90 años; con puntaje T de -1,5 DE, de 0,6% a los 40 años a 3,9% a los 90 años.

**Conclusión:** Los datos muestran la importancia de aplicar herramientas como FRAX, específicas para cada país y también la creación de curvas de evaluación e intervención que permitan discernir según cada paciente la necesidad de utilizar recursos como DXA y tratamientos específicos.

© 2020 Asociación Colombiana de Reumatología. Publicado por Elsevier España, S.L.U.  
Todos los derechos reservados.

### Introduction

Osteoporosis is a systemic disease characterized by loss of mineral bone mass. Due to its prevalence around the world, osteoporosis is considered a serious public health problem. At least 30% of postmenopausal women in the United States and Europe have osteoporosis.<sup>1</sup> About 40% of these women and 15–30% of men will have one or more fragility fractures.<sup>2</sup>

The World Health Organization (WHO) defines the disease according to the measurement of bone mineral density (BMD) by dual x-ray absorptiometry (DXA). BMD values of the femoral neck  $\leq -2.5$  SD are considered osteoporosis.<sup>3,4</sup> The main difficulty in assessing fracture risk is that the T score threshold  $\leq -2.5$  SD has a high specificity but low sensitivity and many of the fragility fractures occur in individuals with BMD values above the osteoporosis threshold.<sup>5</sup>

FRAX is the most widely used fracture risk assessment tool, demonstrating a high predictive capacity.<sup>6</sup> FRAX uses mortality and fracture rates and by combining multiple risk factors (age, sex, body mass index, family history of fracture, alcohol and tobacco consumption, rheumatoid arthritis, use of glucocorticoids and fragility fractures) and the presence or absence of femoral neck DXA, predicts a percentage of fracture risk.<sup>7</sup> The FRAX has been validated and adapted to different countries, covering almost 80% of the world's population,<sup>8</sup> including Ecuador for where it was adapted in 2009.<sup>9</sup>

Due to the great variability in fracture and mortality rates in the different regions, the FRAX model is calibrated based on local epidemiology, which makes it difficult to use

universal intervention thresholds based on FRAX. For example in the study of Maldonado et al. it was found that the risk of major osteoporotic fracture according to FRAX Ecuador was 1.4%, and when the FRAX calculators for Colombia, Brazil and the United States (Hispanic) were applied to the same population, the fracture risk percentages were higher (4.8%, 3.20%, and 2.08% respectively).<sup>10</sup> Due to this difference in values and the new trend of implementing intervention and evaluation curves in the osteoporosis management guidelines,<sup>11,12</sup> the authors launched in July 2017 a proposal of these curves for the Ecuadorian population.<sup>13</sup> In this paper we present the elaboration and application of these curves.

### Methods

Using the FRAX Ecuador model available on the web, we calculated the probability of major osteoporotic fracture and female hip fracture without any risk factor and without the inclusion of BMD. The probabilities were calculated in 5-year intervals from 40 years to 90 years. The BMI was set at  $25 \text{ kg/m}^2$  for all calculations.

Likewise, the probabilities of a major fracture and a hip fracture were calculated in 3 different scenarios:

1. History of prior fracture without the inclusion of BMD.
2. T score  $-2.5$  SD without other clinical risk factors.
3. T score  $-1.5$  SD without other clinical risk factors.

**Table 1 – 10-Year probability of fracture (%) for women with a BMI of 25 kg/m according to age.**

	Osteoporotic										Hip											
	40	45	50	55	60	65	70	75	80	85	90	40	45	50	55	60	65	70	75	80	85	90
No clinical risk factors	0.4	0.5	0.6	0.6	0.8	1.3	2.2	3.7	5.7	7.6	7.3	0	0	0	0.1	0.1	0.3	0.6	1.3	2.6	3.8	3.6
T score -2.5	0.9	1	1.1	1.2	1.5	2	3	4.4	5.6	6.4	5.5	0.4	0.4	0.4	0.4	0.5	0.7	1	1.6	2.4	2.8	2.3
T score -1.5	0.6	0.6	0.7	0.8	0.9	1.2	1.9	2.8	3.6	4.3	3.9	0.1	0.1	0.1	0.1	0.2	0.2	0.4	0.7	1.1	1.5	1.4
Previous fragility fracture	0.9	1.1	1.2	1.4	1.8	2.6	4.3	6.8	9.5	12	12	0.1	0.1	0.2	0.2	0.4	0.7	1.3	2.4	4	5.9	5.6

These scenarios were established based on recommendations from the osteoporosis treatment guidelines. The National Osteoporosis Foundation recommends initiating treatment in patients with a T score  $\leq -2.5$  SD (BMD based intervention threshold).<sup>14</sup> On the other hand, the National Osteoporosis Guideline Group (NOGG) recommends intervention in women with a history of fragility fracture without the need for BMD and in women without prior fracture but with an age-specific FRAX probability equivalent to that of a woman with prior fracture (intervention threshold based on FRAX).<sup>15</sup> The T score -1.5 SD was chosen to represent osteopenia. The probabilities of fracture by age of the intervention thresholds were compared with the specific probabilities by age without clinical risk factors (without the inclusion of BMD).

In addition, the evaluation thresholds for BMD were calculated according to the NOGG. Several studies have shown that the inclusion of BMD in the calculation of the FRAX probability is most useful when the fracture probabilities are close to the intervention threshold,<sup>16,17</sup> that is, in people in whom there is a reasonable probability of that by including BMD in the FRAX calculation their risk of fracture goes from high to low or vice versa. Based on that, the evaluation thresholds were defined as follows:

- The lower evaluation threshold corresponds to the FRAX probabilities for which neither the treatment nor the BMD test should be considered. This was based on the 10-year probability, without BMD, of a major osteoporotic fracture, in women without clinical risk factors, since the guidelines state that people without clinical risk factors should not be considered eligible for evaluation.<sup>18</sup>
- The upper evaluation threshold corresponds to the FRAX probabilities for which treatment can be recommended without the need for BMD. The intervention threshold was set at 1.2 times since Kanis et al.<sup>15</sup> found that when patients have a fracture probability equal to or greater than 20% of

the intervention threshold, the addition of BMD in the calculation of FRAX probability has no greater effect.

## Results

In women without risk factors, the probability of a major osteoporotic fracture increased with age from 0.4% at 40 years to 7.3% at 90 years. Likewise, the probability of hip fracture increased with age from 0% at 40 years to 3.6% at 90 years. The probability of a major osteoporotic fracture increased in women with a T score of -2.5 SD from 0.9% at 40 years to 5.5% at 90 years; with a T-score of -1.5 SD, from 0.6% at 40 years to 3.9% at 90 years; and in women with a history of fracture from 0.9% at 40 years to 12% at 90 years (Table 1).


### Intervention threshold

In 50-year-old women with a T score -2.5 (intervention threshold based on BMD), the probability of osteoporotic fracture was 1.8 times higher than in women of the same age without any risk. As the age progressed, the difference in probabilities between these two groups was decreasing. From the age of 80, the probability of fracture was lower in women with T score -2.5 than in women without risk factors. The same happened with the T-score group -1.5, from the age of 65, the probability of fracture was lower in this group than in women without risk factors. On the other hand, the probability of fracture was consistently higher in the group of women with a history of fracture (intervention threshold based on FRAX), than in women without risk factors (Table 2).


Fig. 1 shows the comparison of intervention curves. As evidenced, the curve corresponding to T-score -2.5 crosses the curve of women without risk factors, thus demonstrating that the intervention threshold using a fixed T score becomes less appropriate as age advances. On the other hand, the FRAX intervention curve with a history of prior fracture is always

**Table 2 – Ratios between FRAX probabilities of major fractures when compared with the group of women without risk factors. The points from which the FRAX probabilities with T score -1.5 and -2.5 are lower than in women without FR are shown in red.**

	40	45	50	55	60	65	70	75	80	85	90
T score -2.5 vs no FR	2.3	2.0	1.8	2.0	1.9	1.5	1.4	1.2	1.0	0.8	0.8
T score -1.5 vs no FR	1.5	1.2	1.2	1.3	1.1	0.9	0.9	0.8	0.6	0.6	0.5
Previous fracture vs no FR	2.3	2.2	2.0	2.3	2.3	2.0	2.0	1.8	1.7	1.6	1.6



**Fig. 1 – 10-year probability (%) of major osteoporotic fracture in Ecuadorian women without risk factors, with a T score of  $-2.5$  SD,  $-1.5$  SD and previous fracture.**



**Fig. 2 – 10-year probability (%) of hip fracture in women of Ecuador without risk factors, with a T score of  $-2.5$  SD,  $-1.5$  SD and with a previous fracture.**

above the curve of women without risk factors. This suggests that the probabilities equivalent to a previous fracture constitute a better reference value above which patients could receive treatment in the absence of a previous fracture.

We found similarities when analyzing the probabilities of hip fracture. From the age of 80, the probability of fracture with a T score  $-2.5$  SD was lower than in women of the same age but without risk factors. With a T score  $-1.5$  this trend was seen from the age of 65 (Fig. 2).

#### Evaluation threshold

According to the NOGG guidelines, the intervention threshold corresponds to the FRAX probability equivalent to a woman with a previous fragility fracture. The lower evaluation threshold was established in the age-specific probabilities of women without clinical risk factors. The superior evaluation was set at 1.2 times the intervention threshold. The three thresholds are shown in Table 3.

Fig. 3 shows the established thresholds based on the FRAX of major osteoporotic fracture. The orange area is where the treatment could be recommended, the gray area is where the treatment would not be recommended and the yellow area is where BMD could be measured to improve the estimation of the risk of fracture.

## Discussion

BMD has proven to be a predictor of fracture risk.<sup>19</sup> For this reason, criteria based on BMD have been adopted as intervention thresholds, however, it is evident that there is a weakness in the use of fixed BMD values. At first, a T score of  $-2.5$  was a strong risk factor for fracture at an early age, but as the age advanced the association with fracture risk decreased. An 80-year-old woman from Ecuador with a T score of  $-2.5$  has a lower probability of fracture than a woman of the same age without any risk factor, which makes the T score  $-2.5$  seem like a fracture protective factor at that age.

Similar results were presented in the study by Johansson et al.<sup>20</sup> since the FRAX probability in 85-year-old women with T score  $-2.5$  was lower than in women without risk factors, while for women with a T score  $-1.5$  the effect was seen from the age of 70. In another study,<sup>21</sup> starting at age 80, a T score of  $-2.5$  SD appeared to be a protective factor for fracture. The reason for this event is the decrease in BMD that occurs with age. In one study it was shown that the average T-score for women of 80 years was less than  $-2.5$ ,<sup>22</sup> demonstrating that in women  $>80$  years old, clinical risk factors alone are enough to make therapeutic decisions. Applying DXA in these age group may have no influence on the fracture risk.


Another problem in recommending treatment only when the BMD T score is  $\leq -2.5$  SD is that the high probability of fracture associated with other risk factors is ignored. For example, treatment should be offered to a 65-year-old woman who smokes and consumes alcohol if she has a T score of  $-2.5$  SD but not with a T score of  $-2.0$ , ignoring the fact that in both cases the probability of fracture (3.2% with T score  $-2.5$  and 2.3% with T score  $-1.5$ ) is higher than the threshold based on BMD (2%). Likewise, a 65-year-old woman with a family history of hip fracture would only be treated if she has a T score of  $-2.5$  SD (Frax 3.5%) but not a T score of  $-2.0$  (FRAX 2.9%).

Finally, the intervention threshold based on BMD makes it necessary to perform densitometries to all patients, which within the country's macroeconomic condition is not routinely accessible. On the other hand, the intervention threshold based on the FRAX has the advantage of making it easy to estimate the probability of fracture within any establishment or situation, without necessarily requiring a bone densitometry test. In the present study, we apply the intervention threshold recommended by the NOGG to the Ecuadorian population based on the probability of age-specific fracture equivalent to that of a woman with a previous fragility fracture. This ranged from 0.9% at 40 years to 12% at 90 years, so women with a FRAX probability equal to or greater than these values should be eligible for treatment without densitometry. For example, a 60-year-old woman with RA who uses corticosteroids even in the absence of BMD should be considered for treatment since her FRAX probability (2%) exceeds that of a woman with a previous fracture (1.8%).

The use of evaluation thresholds proposed by the NOGG improves the risk assessment in patients near the threshold and decreases the number of densitometries required. People with a FRAX probability below the lower evaluation threshold do not require further intervention, while those above the upper evaluation threshold can be considered for treatment

**Table 3 – Assessment threshold for DXA testing in Ecuadorian population.**

Years	Osteoporotic			Hip		
	Intervention threshold	Lower evaluation threshold	Superior evaluation threshold	Intervention threshold	Lower evaluation threshold	Superior evaluation threshold
40	0.9	0.4	1.1	0.1	0.0	0.1
45	1.1	0.5	1.3	0.1	0.0	0.1
50	1.2	0.6	1.4	0.2	0.0	0.2
55	1.4	0.6	1.7	0.2	0.1	0.2
60	1.8	0.8	2.2	0.4	0.1	0.5
65	2.6	1.3	3.1	0.7	0.3	0.8
70	4.3	2.2	5.2	1.3	0.6	1.6
75	6.8	3.7	8.2	2.4	1.3	2.9
80	9.5	5.7	11.4	4.0	2.6	4.8
85	12.0	7.6	14.4	5.9	3.8	7.1
90	12.0	7.3	14.4	5.6	3.6	6.7

**Fig. 3 – Assessment threshold curve for Ecuadorian population, 10-year probability risk of major osteoporotic fracture.**

without densitometry. People with a FRAX probability within the limits of the evaluation thresholds should undergo densitometry and their FRAX should be recalculated using BMD.

In 2017, Clark et al.<sup>23</sup> published the FRAX intervention thresholds of seven Latin American countries, including Ecuador. Our results are similar to those presented in that study, which suggests that there has been no modification of the FRAX Ecuador calculator, although it is evident that the model used underestimates the probability of fracture of the Ecuadorian population. This is because the epidemiology of fractures in Ecuador has changed dramatically. The study that served as a reference for the elaboration of the FRAX Ecuador model reported a crude annual incidence of hip fracture of 49.5 per 100,000 inhabitants, 38.8 per 100,000 men and 63.2 per 100,000 women.<sup>9</sup> In 2018, López et al.<sup>24</sup> reported a Crude annual incidence of 123 cases per 100,000 inhabitants, 74.6 per 100,000 men and 165.8 per 100,000 women, figures that are significantly higher than in the previous study. Likewise, the hospital mortality rate due to hip fracture has increased

from 4.4% in men and 2.9% in women<sup>9</sup> to 5.1% in men and 3.8% in women.<sup>24</sup> Another study by López et al.<sup>25</sup> demonstrated an increase in the rate of mortality from hip fracture from 1.3 per 100,000 women and 2.19 per 100,000 men in 1997 to 6.5 per 100,000 women and 3.5 per 100,000 men in 2016. Due to these changes the revalidation of the FRAX Ecuador calculator is fundamental in order to be applicable to the current reality of the Ecuadorian population.

## Conclusion

Data shows the importance of applying tools such as FRAX, specific for each country and also the creation of evaluation and intervention curves that allow discerning according to each patient the need for the use of resources such as DXA and specific treatments. Due to a possible underestimation of the FRAX calculator in the probability of fracture for the Ecuadorian population, a modification is essential.

## Conflict of interest

The authors declare no conflict of interests.

## REFERENCES

1. Cooper C, Campion G, Melton L. Hip fractures in the elderly: a world-wide projection. *Osteoporos Int.* 1992;2:285-9.
2. Melton L III, Chrischilles E, Cooper C, Lane A, Riggs B, Perspective: How many women have osteoporosis? *Bone Miner Res.* 1992;7:1005-10.
3. Kanis J, Melton L, Christiansen C, Johnston C, Khaltaev N. The diagnosis of osteoporosis. *J Bone Min Res.* 1994;9:1137-41.
4. WHO. Assessment of fracture risk and its application to screening for postmenopausal osteoporosis. Report of a WHO study group. World Health Organ Tech Rep Ser. 1994;843:1-129.
5. Kanis JA, Johnell O, Oden A, Jonsson B, Dawson A, Dere W. Risk of hip fracture derived from relative risks: an analysis applied to the population of Sweden. *Osteoporos Int.* 2000;11:120-7.
6. Schuit SC, van der Klift M, Weel AE, de Laet CEDH, Burger H, Seeman E, et al. Fracture incidence and association with bone mineral density in elderly men and women: the Rotterdam Study [published correction appears in Bone. 2006 Apr;38(4):603]. *Bone.* 2004;34:195-202.
7. Compston J, Cooper A, Cooper C, Gittoes N, Gregson C, Harvey N, et al. UK clinical guideline for the prevention and treatment of osteoporosis. *Arch Osteoporos.* 2017;12:43.
8. Oden A, McCloskey E, Kanis J, Harvey NC. Burden of high fracture probability worldwide: secular increases 2010-2040. *Osteoporos Int.* 2015;26:2243-8.
9. Orces CH. Epidemiology of hip fractures in Ecuador. *Rev Panam Salud Publica.* 2009;25:438-42.
10. Maldonado G, Paredes C, Guerrero R, Mieles M, Intriago M, Messina O, et al. Comparative study of FRAX® score in Ecuadorian population [abstract]. *Arthritis Rheumatol.* 2017;69.
11. Kanis JA, Johnell O, Oden A, Johansson H, McCloskey E. FRAX™ and the assessment of fracture probability in men and women from the UK. *Osteoporos Int.* 2008;19:385-97.
12. Kanis J, McCloskey E, Johansson H, Cooper C, Rizzoli R, Reginster J. European guidance for the diagnosis and management of osteoporosis in postmenopausal women. *Osteoporos Int.* 2013;24:23-57.
13. Maldonado G, Rios C. Propuesta de Curva de Umbrales de Fractura en Población Ecuatoriana. *Reumatol al Día.* 2017;13:18-23.
14. Cosman F, de Beur SJ, LeBoff MS, Lewiecki EM, Tanner B, Randall S, et al. Clinician's guide to prevention and treatment of osteoporosis. *Osteoporos Int.* 2014;25:2359-81.
15. Kanis JA, McCloskey EV, Johansson H, Strom O, Borgstrom F, Oden A. The National Osteoporosis Guideline Group Case finding for the management of osteoporosis with FRAX® - assessment and intervention thresholds for the UK. *Osteoporos Int.* 2008;19:1395-408. Erratum 2009. *Osteoporos Int.* 20:499-502.
16. Leslie WD, Majumdar SR, Lix LM, Johansson H, Oden A, McCloskey E, et al. High fracture probability with FRAX usually indicates densitometric osteoporosis: implications for clinical practice. *Osteoporos Int.* 2012;23:391-7.
17. Kanis JA, McCloskey E, Johansson H, Oden A, Leslie WD. FRAX(R) with and without bone mineral density. *Calcif Tissue Int.* 2012;90:1-13.
18. Kanis JA, Harvey NC, Cooper C, Johansson H, Odén A, McCloskey EV. The advisory board of the national osteoporosis guideline group A systematic review of intervention thresholds based on FRAX. *Arch Osteoporos.* 2016;11:25.
19. Johnell O, Kanis JA, Oden A, Johansson H, De Laet C, Delmas P, et al. Predictive value of BMD for hip and other fractures. *J Bone Miner Res.* 2005;20:1185-94.
20. Johansson H, Azizieh F, Al Ali N, Alessa T, Harvey NC, McCloskey E, et al. FRAX- vs T-score-based intervention thresholds for osteoporosis. *Osteoporos Int.* 2017;28:3099-105.
21. Johansson H, Kanis JA, McCloskey EV, Odén A, Devogelaer JP, Kaufman JM, et al. A FRAX® model for the assessment of fracture probability in Belgium. *Osteoporos Int.* 2011;22:453-61.
22. Johansson H, Oden A, Johnell O, Jonsson B, De Laet C, Oglesby A, et al. Optimisation of BMD measurements to identify high risk groups for treatment—a test analysis. *J Bone Miner Res.* 2004;19:906-13.
23. Clark P, Denova-Gutiérrez E, Zerbini C, Sánchez A, Messina O, Jaller JJ, et al. FRAX-based intervention and assessment thresholds in seven Latin American countries. *Osteoporos Int.* 2018;29:707-15.
24. López Gavilánez E, Chedraui P, Guerrero Franco K, Marriott Blum D, Palacio Riofrío J, Segale Bajaña A. Fracturas osteoporóticas de cadera en adultos mayores en Ecuador 2016. *Rev Osteoporos Metab Miner.* 2018;10:63-70.
25. López Gavilánez E, Guerrero Franco K, Bautista Litardo N, Navarro Chávez M, Hernández Bonilla M, Regalado Alvarado C, et al. In-hospital osteoporotic hip fracture mortality in older adults in Ecuador. *Osteoporos Int.* 2018;29 Suppl. 1:137-553.